Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis

@article{RomeroSnchez2008IdentificationOA,
  title={Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis},
  author={C Romero-S{\'a}nchez and William H Robinson and Beren H. Tomooka and John Makario Londo{\~n}o and Rafael Valle-O{\~n}ate and Feng Huang and Xiaohu Deng and Liyun Y Zhang and Chunhua Yang and David Tak Yan Yu},
  journal={Clinical Rheumatology},
  year={2008},
  volume={27},
  pages={1429-1435}
}
Although most ankylosing spondylitis patients show an apparent clinical response to infliximab therapy, there is considerable individual variation. Because current clinical assessment relies heavily on subjective patient self-evaluation, biomarkers of high sensitivity and specificity are much needed. Here, we assessed potential biomarkers in 47 ankylosing spondylitis patients who received three standard pulses of infliximab. Before each infusion and at week 10, the following were measured… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 21 REFERENCES

a systematic review and economic evaluation

  • C McLeod, A Bagust, Boland A et al Adalimumab, etanercept, infliximab for the treatment of ankylosing spondylitis
  • Health Technol Assess 11:1–158 1434 Clin…
  • 2008
2 Excerpts

Similar Papers

Loading similar papers…